Hellyer JA - Search Results

1

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.

Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, McCoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW Jr, Diehn M, Han SS, Wakelee HA. Aredo JV, et al. Among authors: hellyer ja. J Thorac Oncol. 2021 Jun;16(6):1030-1041. doi: 10.1016/j.jtho.2021.01.1628. Epub 2021 Feb 12. J Thorac Oncol. 2021. PMID: 33588109 Free article.

2

Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.

Hellyer JA, Stehr H, Das M, Padda SK, Ramchandran K, Neal JW, Diehn M, Wakelee HA. Hellyer JA, et al. Lung Cancer. 2019 Aug;134:42-45. doi: 10.1016/j.lungcan.2019.05.002. Epub 2019 May 3. Lung Cancer. 2019. PMID: 31319993

3

Everolimus in the treatment of metastatic thymic epithelial tumors.

Hellyer JA, Ouseph MM, Padda SK, Wakelee HA. Hellyer JA, et al. Lung Cancer. 2020 Nov;149:97-102. doi: 10.1016/j.lungcan.2020.09.006. Epub 2020 Sep 17. Lung Cancer. 2020. PMID: 33007678

4

Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC.

Hellyer JA, Padda SK, Diehn M, Wakelee HA. Hellyer JA, et al. J Thorac Oncol. 2021 Mar;16(3):395-403. doi: 10.1016/j.jtho.2020.11.015. Epub 2020 Dec 8. J Thorac Oncol. 2021. PMID: 33307193 Free article. Review.

5

Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.

Hellyer JA, Aredo JV, Das M, Ramchandran K, Padda SK, Neal JW, Wakelee HA. Hellyer JA, et al. J Thorac Oncol. 2021 May;16(5):868-872. doi: 10.1016/j.jtho.2020.12.020. Epub 2021 Feb 1. J Thorac Oncol. 2021. PMID: 33539970 Free article.

6

Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.

Aredo JV, Hellyer JA, Neal JW, Wakelee HA. Aredo JV, et al. Among authors: hellyer ja. J Thorac Oncol. 2021 Dec;16(12):1994-1998. doi: 10.1016/j.jtho.2021.07.033. J Thorac Oncol. 2021. PMID: 34809803 Free article. No abstract available.

7

Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.

Hellyer JA, White MN, Gardner RM, Cunanan K, Padda SK, Das M, Ramchandran K, Neal JW, Wakelee HA. Hellyer JA, et al. Clin Lung Cancer. 2022 May;23(3):264-272. doi: 10.1016/j.cllc.2021.09.004. Epub 2021 Oct 21. Clin Lung Cancer. 2022. PMID: 34838441

8

Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.

Jeong Y, Hellyer JA, Stehr H, Hoang NT, Niu X, Das M, Padda SK, Ramchandran K, Neal JW, Wakelee H, Diehn M. Jeong Y, et al. Among authors: hellyer ja. Clin Cancer Res. 2020 Jan 1;26(1):274-281. doi: 10.1158/1078-0432.CCR-19-1237. Epub 2019 Sep 23. Clin Cancer Res. 2020. PMID: 31548347 Free PMC article.

9

Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.

Hellyer JA, Gubens MA, Cunanan KM, Padda SK, Burns M, Spittler AJ, Riess JW, San Pedro-Salcedo M, Ramchandran KJ, Neal JW, Wakelee HA, Loehrer PJ Sr. Hellyer JA, et al. Lung Cancer. 2019 Nov;137:71-75. doi: 10.1016/j.lungcan.2019.09.015. Epub 2019 Sep 18. Lung Cancer. 2019. PMID: 31557562 Clinical Trial.

10

Adjuvant Chemotherapy.

Hellyer JA, Wakelee HA. Hellyer JA, et al. Thorac Surg Clin. 2020 May;30(2):179-185. doi: 10.1016/j.thorsurg.2020.01.003. Epub 2020 Mar 2. Thorac Surg Clin. 2020. PMID: 32327176 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters